Invention Grant
- Patent Title: RNA interference for the treatment of heart failure
- Patent Title (中): RNA干扰治疗心力衰竭
-
Application No.: US12811306Application Date: 2008-12-23
-
Publication No.: US08404658B2Publication Date: 2013-03-26
- Inventor: Roger J. Hajjar , Wolfgang Ch. Poller , Henry Fechner
- Applicant: Roger J. Hajjar , Wolfgang Ch. Poller , Henry Fechner
- Applicant Address: US NC Chapel Hill
- Assignee: NanoCor Therapeutics, Inc.
- Current Assignee: NanoCor Therapeutics, Inc.
- Current Assignee Address: US NC Chapel Hill
- Agency: Edwards Wildman Palmer LLP
- Agent Peter C. Lauro, Esq.; Melissa Hunter-Ensor, Esq.
- International Application: PCT/US2008/088248 WO 20081223
- International Announcement: WO2009/088786 WO 20090716
- Main IPC: C12N15/11
- IPC: C12N15/11
Abstract:
The present invention relates to targeted RNAi for the treatment of heart failure by modulating defective cardiac Ca2+ homeostasis via decreasing expression or activity of phospholamban (PLB) using adeno-associated virus (AAV) transfection of cardiomyocytes. Methods for decreasing ventricular arrhythmias, as well as methods for overall improvement of survival from heart failure in subjects are also disclosed. Further, the present invention provides methods which can be used to diagnose susceptibility to treatment by RNAi, and includes pharmaceutical compositions, kits and vectors including an RNAi sequence.
Public/Granted literature
- US20110098338A1 RNA Interference for the Treatment of Heart Failure Public/Granted day:2011-04-28
Information query
IPC分类:
